Stocksigma LogoStocksigma Logo

Windlas Biotech Q2 FY27 Results and Board Leadership Restructuring

Windlas Biotech reported Q2 FY27 revenue from operations of ₹2,639.08m, up 18.7% YoY from ₹2,223.98m and 6.4% QoQ from ₹2,480.99m

Windlas Biotech Q2 FY27 Results and Board Leadership Restructuring

Windlas Biotech Ltd · Change in Management · 05 Nov 2026, 10:55 pm

Windlas Biotech Q2 FY27 Results and Board Leadership Restructuring Windlas Biotech reported Q2 FY27 revenue from operations of ₹2,639.08m, up 18.7% YoY from ₹2,223.98m and 6.4% QoQ from ₹2,480.99m. Net profit reached ₹180.52m compared to ₹178.00m in Q2 FY26 and ₹176.53m in Q1 FY27, with diluted EPS at ₹8.56. In leadership changes, MD Hitesh Windlass was appointed Chairman effective 5th Nov'26, while founder Ashok Kumar Windlass stepped down as Whole-time Director to transition into the Senior Management Personnel role of Founder President from 6th Nov'26.

Original exchange filing (PDF)

More announcements from Windlas Biotech Ltd

All Windlas Biotech Ltd announcements